Anti-cancer potential of a novel SERM ormeloxifene

Rishi Kumar Gara, Vasudha Sundram, Subhash Chauhan, Meena Jaggi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Ormeloxifene is a non-steroidal Selective Estrogen Receptor Modulator (SERM) that is used as an oral contraceptive. Recent studies have shown its potent anti-cancer activities in breast, head and neck, and chronic myeloid leukemia cells. Several in vivo and clinical studies have reported that ormeloxifene possesses an excellent therapeutic index and has been well-tolerated, without any haematological, biochemical or histopathological toxicity, even with chronic administration. A reasonably long period of time and an enormous financial commitment are required to develop a lead compound into a clinically approved anti-cancer drug. For these reasons and to circumvent these obstacles, ormeloxifene is a promising candidate on a fast track for the development or repurposing established drugs as anti-cancer agents for cancer treatment. The current review summarizes recent findings on ormeloxifene as an anti-cancer agent and future prospects of this clinically safe pharmacophore.

Original languageEnglish (US)
Pages (from-to)4177-4184
Number of pages8
JournalCurrent Medicinal Chemistry
Volume20
Issue number33
DOIs
StatePublished - Nov 1 2013

Fingerprint

Selective Estrogen Receptor Modulators
Neoplasms
Lead compounds
Non-Steroidal Estrogens
Drug Repositioning
Oncology
Oral Contraceptives
Pharmaceutical Preparations
Toxicity
Myeloid Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Breast
Neck
Head
ormeloxifene

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Anti-cancer potential of a novel SERM ormeloxifene. / Gara, Rishi Kumar; Sundram, Vasudha; Chauhan, Subhash; Jaggi, Meena.

In: Current Medicinal Chemistry, Vol. 20, No. 33, 01.11.2013, p. 4177-4184.

Research output: Contribution to journalArticle

Gara, Rishi Kumar ; Sundram, Vasudha ; Chauhan, Subhash ; Jaggi, Meena. / Anti-cancer potential of a novel SERM ormeloxifene. In: Current Medicinal Chemistry. 2013 ; Vol. 20, No. 33. pp. 4177-4184.
@article{79d6f3f76d5a47d6b394b9d31db73a00,
title = "Anti-cancer potential of a novel SERM ormeloxifene",
abstract = "Ormeloxifene is a non-steroidal Selective Estrogen Receptor Modulator (SERM) that is used as an oral contraceptive. Recent studies have shown its potent anti-cancer activities in breast, head and neck, and chronic myeloid leukemia cells. Several in vivo and clinical studies have reported that ormeloxifene possesses an excellent therapeutic index and has been well-tolerated, without any haematological, biochemical or histopathological toxicity, even with chronic administration. A reasonably long period of time and an enormous financial commitment are required to develop a lead compound into a clinically approved anti-cancer drug. For these reasons and to circumvent these obstacles, ormeloxifene is a promising candidate on a fast track for the development or repurposing established drugs as anti-cancer agents for cancer treatment. The current review summarizes recent findings on ormeloxifene as an anti-cancer agent and future prospects of this clinically safe pharmacophore.",
author = "Gara, {Rishi Kumar} and Vasudha Sundram and Subhash Chauhan and Meena Jaggi",
year = "2013",
month = "11",
day = "1",
doi = "10.2174/09298673113209990197",
language = "English (US)",
volume = "20",
pages = "4177--4184",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "33",

}

TY - JOUR

T1 - Anti-cancer potential of a novel SERM ormeloxifene

AU - Gara, Rishi Kumar

AU - Sundram, Vasudha

AU - Chauhan, Subhash

AU - Jaggi, Meena

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Ormeloxifene is a non-steroidal Selective Estrogen Receptor Modulator (SERM) that is used as an oral contraceptive. Recent studies have shown its potent anti-cancer activities in breast, head and neck, and chronic myeloid leukemia cells. Several in vivo and clinical studies have reported that ormeloxifene possesses an excellent therapeutic index and has been well-tolerated, without any haematological, biochemical or histopathological toxicity, even with chronic administration. A reasonably long period of time and an enormous financial commitment are required to develop a lead compound into a clinically approved anti-cancer drug. For these reasons and to circumvent these obstacles, ormeloxifene is a promising candidate on a fast track for the development or repurposing established drugs as anti-cancer agents for cancer treatment. The current review summarizes recent findings on ormeloxifene as an anti-cancer agent and future prospects of this clinically safe pharmacophore.

AB - Ormeloxifene is a non-steroidal Selective Estrogen Receptor Modulator (SERM) that is used as an oral contraceptive. Recent studies have shown its potent anti-cancer activities in breast, head and neck, and chronic myeloid leukemia cells. Several in vivo and clinical studies have reported that ormeloxifene possesses an excellent therapeutic index and has been well-tolerated, without any haematological, biochemical or histopathological toxicity, even with chronic administration. A reasonably long period of time and an enormous financial commitment are required to develop a lead compound into a clinically approved anti-cancer drug. For these reasons and to circumvent these obstacles, ormeloxifene is a promising candidate on a fast track for the development or repurposing established drugs as anti-cancer agents for cancer treatment. The current review summarizes recent findings on ormeloxifene as an anti-cancer agent and future prospects of this clinically safe pharmacophore.

UR - http://www.scopus.com/inward/record.url?scp=84887884997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887884997&partnerID=8YFLogxK

U2 - 10.2174/09298673113209990197

DO - 10.2174/09298673113209990197

M3 - Article

VL - 20

SP - 4177

EP - 4184

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 33

ER -